Authors (including presenting author) :
CHANG HY (1), NG CL (1)
Affiliation :
(1)KWC FM & PHC
Introduction :
As sodium glucose co-transporter 2 inhibitors (SGLT2i) is a relatively new class of second-line oral hypoglycaemic agent, it is essential to ensure patient and medication safety when prescribing it by enhancing relevant medical knowledge
Objectives :
To enhance medical knowledge with updated international recommendations when prescribing SGLT2-i and to improve patient and medication safety in the prescription of SGLT2-i.
Methodology :
The audit protocol was set up with reference to international and local guidelines and recommendations. The audit protocol includes 6 criteria which are during the pre-treatment stage, eGFR within 6 months should be checked and documentation of no history of diabetic ketoacidosis (DKA) in consultation notes; on initiation, signs and symptoms of DKA and urogenital infection should be explained and educated with a drug pamphlet distributed; during follow-up, side effects of urogenital infection should be checked. Data was generated using the Clinical Data Analysis and Reporting System (CDARS). Subsequently, data was inputted into Microsoft Excel for analysis.
To remind colleagues and myself about the audit criteria, the results of 1st cycle were presented in the clinic meeting, printed audit protocol and drug pamphlets of SGLT2-i were placed in all consultation rooms.
Result & Outcome :
After implementation of changes by preparing printed audit protocol and printing pamphlets, 2nd cycle data reached up to 97% in 5 of the audit criteria and there is room for improvement on pamphlet distribution.
This clinical audit allows me to enhance medical knowledge with updated international and local recommendations when prescribing SGLT2-i. Also, the result of the 2nd cycle reveals that patient and medication safety in the prescription of SGLT2-i is improved.
